Percutaneous absorption of a new antiandrogen included in liposomes or in solution

In 1995, a study was conducted to compare the absorption and distribution of a new antiandrogen, RU 58841, when included in liposomes or in solution. The study found that liposomes significantly reduced the percutaneous absorption of RU 58841 compared to the solution, but resulted in slower permeation of the drug and a longer duration in the skin. Liposomes also led to an accumulation of the drug in the sebaceous structures. The study concluded that liposomes could be more favorable for topical application as they reduce absorption, increase retention of the drug in the skin, and target the sebaceous structures.